Went public 10/12/00 at $8 per share
Filing Range:5.0 million shares @ $8 to $10
Shares Outstanding:20.46 million shares
Underwriters: SG Cowen Securities/PaineWebber/Prudential Vector Healthcare
Company Counsel: Wilson Sonsini Goodrich & Rosati
Manager Counsel: Shearman & Sterling
Auditor: Arthur Andersen & Co.
Develops gene therapy products for the treatment of cancer. Introgen
Therapeutics’ drug discovery and development programs have resulted in innovative approaches in which physicians use genes to treat cancer by directly addressing the genetic abnormalities associated with the disease.
Nomura Overseas Enterprises
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 08/01/1994 1 Early Stage 527.0
2 03/01/1996 2 Early Stage 14496.0
3 06/01/1996 2 Expansion 4770.0
4 10/01/1997 2 Expansion 11000.0
(Data in $ millions)
Total Revenues: $8.4
Net Income: -7.7